A Dual Pharmacological Strategy Against COVID-19: The Therapeutic Potential of Metformin and Atorvastatin

Metformin (MET) and atorvastatin (ATO) are promising treatments for COVID-19. This review explores the potential of MET and ATO, commonly prescribed for diabetes and dyslipidemia, respectively, as versatile medicines against SARS-CoV-2. Due to their immunomodulatory and antiviral capabilities, as well as their cost-effectiveness and ubiquitous availability, they are highly suitable options for treating the virus. MET's effect extends beyond managing blood sugar, impacting pathways that can potentially decrease the severity and fatality rates linked with COVID-19. It can partially block mitochondrial complex I and stimulate AMPK, which indicates that it can be used more widely in managing viral infections. ATO, however, impacts cholesterol metabolism, a crucial element of the viral replicative cycle, and demonstrates anti-inflammatory characteristics that could modulate intense immune reactions in individuals with COVID-19. Retrospective investigations and clinical trials show decreased hospitalizations, severity, and mortality rates in patients receiving these medications. Nevertheless, the journey from observing something to applying it in a therapeutic setting is intricate, and the inherent diversity of the data necessitates carefully executed, forward-looking clinical trials. This review highlights the requirement for efficacious, easily obtainable, and secure COVID-19 therapeutics and identifies MET and ATO as promising treatments in this worldwide health emergency.

Citing Articles

Advances and Challenges in Antiviral Development for Respiratory Viruses.

De Jesus-Gonzalez L, Leon-Juarez M, Lira-Hernandez F, Rivas-Santiago B, Velazquez-Cervantes M, Mendez-Delgado I Pathogens. 2025; 14(1).

PMID: 39860981 PMC: 11768830. DOI: 10.3390/pathogens14010020.

Metformin in Antiviral Therapy: Evidence and Perspectives.

Halabitska I, Petakh P, Lushchak O, Kamyshna I, Oksenych V, Kamyshnyi O Viruses. 2025; 16(12.

PMID: 39772244 PMC: 11680154. DOI: 10.3390/v16121938.

Targeting AMP-activated protein kinase in sepsis.

Yumoto T, Coopersmith C Front Endocrinol (Lausanne). 2024; 15:1452993.

PMID: 39469575 PMC: 11513325. DOI: 10.3389/fendo.2024.1452993.

Acute Kidney Injury in the Context of COVID-19: An Analysis in Hospitalized Mexican Patients.

Borrego-Moreno J, Cardenas-de Luna M, Marquez-Castillo J, Reyes-Ruiz J, Osuna-Ramos J, Leon-Juarez M Infect Dis Rep. 2024; 16(3):458-471.

PMID: 38804444 PMC: 11130795. DOI: 10.3390/idr16030034.

Association between lipid profile and clinical outcomes in COVID-19 patients.

Ochoa-Ramirez L, De la Herran Arita A, Sanchez-Zazueta J, Rios-Burgueno E, Murillo-Llanes J, De Jesus-Gonzalez L Sci Rep. 2024; 14(1):12139.

PMID: 38802549 PMC: 11130121. DOI: 10.1038/s41598-024-62899-y.

References

Lee H, Noh J, Song J, Cheong H, Kim W . Metformin reduces the risk of developing influenza A virus related cardiovascular disease. Heliyon. 2023; 9(10):e20284. PMC: 10556598. DOI: 10.1016/j.heliyon.2023.e20284. View

Liu X, Yu P, Xu Y, Wang Y, Chen J, Tang F . Metformin induces tolerogenicity of dendritic cells by promoting metabolic reprogramming. Cell Mol Life Sci. 2023; 80(10):283. PMC: 10492886. DOI: 10.1007/s00018-023-04932-3. View

Guan J, Sun X, Liang Y, Dong W, Zhang L, Zhu J . Atorvastatin attenuates Coxsackie virus B3m-induced viral myocarditis in mice. J Cardiovasc Pharmacol. 2010; 56(5):540-7. DOI: 10.1097/FJC.0b013e3181f6b28d. View

Hoppe-Seyler K, Herrmann A, Daschle A, Kuhn B, Strobel T, Lohrey C . Effects of Metformin on the virus/host cell crosstalk in human papillomavirus-positive cancer cells. Int J Cancer. 2021; 149(5):1137-1149. DOI: 10.1002/ijc.33594. View

Sorathia N, Al-Rubaye H, Zal B . The Effect of Statins on the Functionality of CD4+CD25+FOXP3+ Regulatory T-cells in Acute Coronary Syndrome: A Systematic Review and Meta-analysis of Randomised Controlled Trials in Asian Populations. Eur Cardiol. 2019; 14(2):123-129. PMC: 6659032. DOI: 10.15420/ecr.2019.9.2. View

Calza L, Trapani F, Bartoletti M, Manfredi R, Colangeli V, Borderi M . Statin therapy decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factor-α in HIV-infected patients treated with ritonavir-boosted protease inhibitors. HIV Clin Trials. 2012; 13(3):153-61. DOI: 10.1310/hct1303-153. View

Palacios-Rapalo S, Farfan-Morales C, Cordero-Rivera C, De Jesus-Gonzalez L, Reyes-Ruiz J, Meraz-Rios M . An ivermectin - atorvastatin combination impairs nuclear transport inhibiting dengue infection and . iScience. 2023; 26(12):108294. PMC: 10682259. DOI: 10.1016/j.isci.2023.108294. View

Granato M, Gilardini Montani M, Romeo M, Santarelli R, Gonnella R, DOrazi G . Metformin triggers apoptosis in PEL cells and alters bortezomib-induced Unfolded Protein Response increasing its cytotoxicity and inhibiting KSHV lytic cycle activation. Cell Signal. 2017; 40:239-247. DOI: 10.1016/j.cellsig.2017.09.020. View

Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong J, Turner A . Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ Res. 2020; 126(10):1456-1474. PMC: 7188049. DOI: 10.1161/CIRCRESAHA.120.317015. View

10.

Jiang Z, Liu H . Metformin inhibits tumorigenesis in HBV-induced hepatocellular carcinoma by suppressing HULC overexpression caused by HBX. J Cell Biochem. 2017; 119(6):4482-4495. DOI: 10.1002/jcb.26555. View

11.

Planas D, Pagliuzza A, Ponte R, Fert A, Raymond Marchand L, Massanella M . LILAC pilot study: Effects of metformin on mTOR activation and HIV reservoir persistence during antiretroviral therapy. EBioMedicine. 2021; 65:103270. PMC: 7930590. DOI: 10.1016/j.ebiom.2021.103270. View

12.

Moreno-Corona N, Lopez-Ortega O, Perez-Martinez C, Martinez-Castillo M, De Jesus-Gonzalez L, Leon-Reyes G . Dynamics of the Microbiota and Its Relationship with Post-COVID-19 Syndrome. Int J Mol Sci. 2023; 24(19). PMC: 10573029. DOI: 10.3390/ijms241914822. View

13.

Davoodi L, Jafarpour H, Oladi Z, Zakariaei Z, Tabarestani M, Ahmadi B . Atorvastatin therapy in COVID-19 adult inpatients: A double-blind, randomized controlled trial. Int J Cardiol Heart Vasc. 2021; 36:100875. PMC: 8437805. DOI: 10.1016/j.ijcha.2021.100875. View

14.

Scheen A . Metformin and COVID-19: From cellular mechanisms to reduced mortality. Diabetes Metab. 2020; 46(6):423-426. PMC: 7395819. DOI: 10.1016/j.diabet.2020.07.006. View

15.

Kumar V, Liu H, Wu C . Drug repurposing against SARS-CoV-2 receptor binding domain using ensemble-based virtual screening and molecular dynamics simulations. Comput Biol Med. 2021; 135:104634. PMC: 8257406. DOI: 10.1016/j.compbiomed.2021.104634. View

16.

Fontaine E . Metformin-Induced Mitochondrial Complex I Inhibition: Facts, Uncertainties, and Consequences. Front Endocrinol (Lausanne). 2019; 9:753. PMC: 6304344. DOI: 10.3389/fendo.2018.00753. View

17.

Ikeda M, Kato N . Life style-related diseases of the digestive system: cell culture system for the screening of anti-hepatitis C virus (HCV) reagents: suppression of HCV replication by statins and synergistic action with interferon. J Pharmacol Sci. 2007; 105(2):145-50. DOI: 10.1254/jphs.fm0070050. View

18.

Li G, Hilgenfeld R, Whitley R, De Clercq E . Therapeutic strategies for COVID-19: progress and lessons learned. Nat Rev Drug Discov. 2023; 22(6):449-475. PMC: 10113999. DOI: 10.1038/s41573-023-00672-y. View

19.

Conde K, Pineda G, Newton R, Fernandez M . Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin. Biochem Pharmacol. 1999; 58(7):1209-19. DOI: 10.1016/s0006-2952(99)00203-8. View

20.

Al-Kuraishy H, Al-Gareeb A, Saad H, El-Saber Batiha G . The potential therapeutic effect of statins in multiple sclerosis: beneficial or detrimental effects. Inflammopharmacology. 2023; 31(4):1671-1682. DOI: 10.1007/s10787-023-01240-x. View